Results 11 to 20 of about 126,534 (277)

Potential role of glucagon like peptide 1 in taste receptors [PDF]

Frontiers in Endocrinology
The perception of taste is a complex physiological process that extends far beyond the simple detection of flavor molecules, serving as a critical interface between nutrient sensing, metabolic regulation, and feeding behavior.
Jose Luis Eduardo Doval-Caballero, Aldo Ferreira-Hermosillo, Genesis Dinora Eugenio-Ponce, Manuel Ramon García-Sáenz, Raúl Ibarra-Salce, Andrea Patricia Tenorio-Rojo, Eduardo Salif Luna-Avila, Paulo César Gete-Palacios, Fernando Pérez-Hernández, Eduardo Rojas-Milán, Luis Angel López-Cruz, César Alejandro Méndez-Hernández   +11 more
doaj   +2 more sources

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias [PDF]

Journal of Arrhythmia
Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks.
Vikash Jaiswal, Muhammad Hanif, Aman Goyal, Juveriya Yasmeen, Vamsi Garimella, Yusra Mashkoor, Roopeessh Vempati, Novonil Deb, Yusra Minahil Nasir, Kripa Rajak, Abhigan Babu Shrestha, Jishanth Mattumpuram, Andrew Weinberg   +12 more
doaj   +2 more sources

Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects [PDF]

Annals of Pediatric Endocrinology & Metabolism
Ever since its discovery, glucagon-like-peptide 1 (GLP-1) and drugs with similar function (collectively GLP-1s) have been used for type 2 diabetes mellitus and have been effective for obesity.
Kyu Sik Kim, Joon Seok Park, Hyung Jin Choi   +2 more
doaj   +2 more sources

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea [PDF]

Obesity Science & Practice
Background and Aim Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are well‐established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA).
Bei‐Bei Qian, Yu‐Jie Huang, Cai‐Feng Yan, Shang‐Yong Feng, Dun‐Min She   +4 more
doaj   +2 more sources

A walnut-containing meal had similar effects on early satiety, CCK, and PYY, but attenuated the postprandial GLP-1 and insulin response compared to a nut-free control meal. [PDF]

, 2017
Regular nut consumption is associated with lower adiposity and reduced weight gain in adulthood. Walnut feeding studies have observed minimal effect on body weight despite potential additional energy intake.
Barkai, Hava-Shoshana, Flatt, Shirley W, Heath, Dennis D, Pakiz, Bilge, Rock, Cheryl L   +4 more
core   +2 more sources

Glucagon-Like Peptide-1

Recent Progress in Hormone Research, 2001
There is a progressive impairment in beta-cell function with age. As a result, 19 percent of the U.S. population over the age of 65 is diagnosed with type 2 diabetes mellitus (DM). Glucagon-like peptide-1 (GLP-1) is a potent insulin secretagogue that has multiple synergetic effects on the glucose-dependent insulin secretion pathways of the beta-cell ...
M E, Doyle, J M, Egan
openaire   +2 more sources

Direct cardiovascular effects of glucagon like peptide-1 [PDF]

, 2013
Current gold standard therapeutic strategies for T2DM target insulin resistance or β cell dysfunction as their core mechanisms of action. However, the use of traditional anti-diabetic drugs, in most cases, does not significantly reduce macrovascular ...
Asfandyar Sheikh
core   +1 more source

Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1 [PDF]

, 2011
The glucagon gene (GCG) encodes several hormones important for energy metabolism: glucagon, oxyntomodulin and glucagon-like peptide (GLP)-1 and -2.
A. Linneberg, A. Sandbaek, B. Hartmann, D. R. Witte, H. Kissow, I. A. Hainerová, J. J. Holst, J. Lebl, J. Wang, L. Ma, M. Rosenkilde, N. Grarup, null null, O. D. Madsen, O. Pedersen, S. Madsbad, S. S. Torekov, T. Hansen, T. Jørgensen, T. Lauritzen, U. Kielgast   +20 more
core   +1 more source

CARDIOVASCULAR AND HEMODYNAMIC EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 [PDF]

, 2014
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has been shown to have hemodynamic and cardioprotective capacity in addition to its better characterized glucoregulatory actions. Because of this, emerging research has focused on the ability of
Conteh, Abass M., Goodwill, Adam G., Mather, Kieren J., Noblet, Jillian N., Sassoon, Daniel, Tune, Johnathan D.   +5 more
core   +1 more source

Glucagon-like peptide 1 and appetite [PDF]

Trends in Endocrinology & Metabolism, 2013
Glucagon-like peptide 1 (GLP-1) and GLP-1 analogs have received much recent attention due to the success of GLP-1 mimetics in treating type II diabetes mellitus (T2DM), but these compounds may also have the potential to treat obesity. The satiety effect of GLP-1 may involve both within-meal enteroenteric reflexes, and across-meal central signaling ...
Megan J, Dailey, Timothy H, Moran
openaire   +2 more sources